Compare MNKD & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNKD | MPLT |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.6M | 811.3M |
| IPO Year | 2004 | N/A |
| Metric | MNKD | MPLT |
|---|---|---|
| Price | $2.72 | $26.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $8.56 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 4.5M | 240.6K |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $35.81 | N/A |
| Revenue Next Year | $11.89 | N/A |
| P/E Ratio | $138.50 | ★ N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $12.24 |
| 52 Week High | $6.51 | $30.28 |
| Indicator | MNKD | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 69.43 |
| Support Level | $2.52 | $16.19 |
| Resistance Level | $4.09 | N/A |
| Average True Range (ATR) | 0.11 | 2.09 |
| MACD | 0.11 | 0.55 |
| Stochastic Oscillator | 88.99 | 74.10 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.